Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Jan 27;18:39. doi: 10.1186/s12882-017-0461-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2017

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 6 — Clinical outcomes of kidney transplant recipients according to the AKI stage by either the KDIGO or AKIN criteria in corresponding donors. The incidence of DGF was highest in stage 3 AKI by either the (a) KDIGO or (b) AKIN criteria. The changing patterns of allograft function in each AKI stage group according to the AKI stage in corresponding donors by the (c) KDIGO or (d) AKIN criteria. Please note that allograft function was lowest in the stage 3 AKI group and highest in the non-AKI group in both analyses by 6 months after KT. But these differences disappeared at 1 year from KT. The allograft survival rate in each AKI stage group according to the AKI stage in corresponding donors by the (e) KDIGO or (f) AKIN criteria. Please note that there was no significant difference in long term allograft survival rate among each AKI stage group in both analyses. MDRD, the modification of diet in renal disease; eGFR, estimated glomerular filtration rate; DGF, delayed graft function; AKI, acute kidney injury; KDIGO, kidney disease: improving global outcome; AKIN, acute kidney injury network; d, day; m, month. ^* P <0.05 compared with non-AKI, ^† P < 0.05 compared with AKI stage 1, ^‡ P <0.05 compared with non-AKI, ^§ P <0.05 AKI stage 1 compared with non-AKI, ^II P <0.05 AKI stage 3 compared with non-AKI, ^¶ P <0.05 AKI stage 3 compared with non-AKI